According to incomplete statistics from Innovation Radar, last week (June 30 to July 6) in the global pharmaceuticals and healthcare fieldA total of 24 financing events were disclosed, with a total financing amount exceeding $6.4 billion.。

Last week, there were two financings in the metabolic disease field.Maike Aote Secures Over 100 Million Yuan in D-Round Funding, Committed to Developing Bifunctional and Multifunctional Specific Peptide DrugsCurrently, seven pipelines have entered the clinical research and development stage.

Another companySyntis Bio Announces Completion of $33 Million Series A FinancingThe company focuses on developing oral targeted drugs for the treatment of obesity, diabetes, and rare diseases, with drug designs that precisely target the small intestine. The core project, SYNT-101, is a once-daily oral weight-loss medication that temporarily blocks nutrient absorption in the upper small intestine (duodenum) and redirects nutrients to the lower small intestine, thereby stimulating the natural secretion of satiety and metabolic regulatory hormones. The company is also advancing the development of other drugs for metabolic diseases.

Cloudbreak Pharma Officially Listed on HKEX, Raising a Total of HKD 612 MillionThe company has a Multi-Kinase Inhibitor (MKI) platform to develop small-molecule drugs targeting angiogenesis for treating ocular indications involving abnormal angiogenesis or vascular distribution. Additionally, the company owns an antibody-drug synergy platform focusing on antibody-small molecule drug conjugates. Currently, Cloudbreak Pharma has four drugs in clinical stages. Its core pipeline product, CBT-001, is a multi-kinase inhibitor used for preventing the progression of pterygium and reducing conjunctival hyperemia, and it is currently in Phase 3 clinical trials.

Another ophthalmology newcomer, FELIQS, has simultaneously completed a $9 million Series A financing round.The company focuses on developing small-molecule therapies targeting oxidized lipids. Its core pipeline, FLQ-101, aims to prevent retinopathy of prematurity, a disease that can cause blindness in premature infants. The drug promotes physiological retinal vascularization and inhibits inflammation and abnormal neovascularization. It has already been granted Fast Track and Orphan Drug designations by the U.S. FDA.

Readers, please star⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle individually, unauthorized media or institutions are prohibited to reprint/reproduce in any form to other platforms. For reprint authorization, please contact"Chuangjian Hui"Contact us via the WeChat Official Account message.

More Data Content Recommendations

Click "InSee", Sharing the Latest Health Trends from Creatrust Digest